{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:36:57Z","timestamp":1793093817062,"version":"4.5.0"},"reference-count":38,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec id=\"S0317167125104095_as1\">\n                    <jats:title>Background and objectives:<\/jats:title>\n                    <jats:p>Neurofibromatosis type 1 (NF1) is a genetic disorder. Up to 50% of NF1 patients develop plexiform neurofibromas (PN). Despite revisions in diagnostic standards, there remains a lack of consensus on referral, treatment, monitoring and transition processes for NF1-PN. The study aimed to establish a Canada-wide consensus on the best practice for referral and management of patients with NF1-PN to help generate guidance where evidence on the long-term use of MEK inhibitors is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167125104095_as2\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study used a modified Delphi method. The steering committee (SC) identified 4 topics of focus and developed 44 consensus statements. Following ratification, 43 statements were developed into an online survey sent to 113 healthcare practitioners (HCPs) involved in NF1-PN management across Canada. Respondents used a 4-point Likert scale to indicate agreement with each statement. The threshold for consensus agreement was 75%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167125104095_as3\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 56 responses were received, predominantly from Ontario. Most respondents were neuro-oncologists (34%) and had over 11 years of experience (57%). Consensus was reached on 41 of 43 statements (95%), enabling the SC to develop recommendations for NF1-PN patient care and a treatment algorithm outlining key timings for treatment and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167125104095_as4\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>To our knowledge, this is the first national Delphi consensus on NF1-PN. Strong agreement was seen from HCPs on critical timings in NF1-PN treatment and management. The proposed recommendations and treatment algorithm provide a framework to enhance patient care and support ongoing research into optimizing care for NF1-PN patients, not just in Canada but globally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/cjn.2025.10409","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T08:07:46Z","timestamp":1756800466000},"page":"708-716","source":"Crossref","is-referenced-by-count":3,"title":["A National Modified Delphi Consensus on the Referral and Management of NF1 Plexiform Neurofibroma"],"prefix":"10.1017","volume":"53","author":[{"given":"Lucie","family":"Lafay-Cousin","sequence":"first","affiliation":[{"name":"Alberta Children\u2019s Hospital"},{"name":"University of Calgary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Perreault","sequence":"additional","affiliation":[{"name":"CHU Sainte-Justine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dal","family":"Singh","sequence":"additional","affiliation":[{"name":"Triducive Partners Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4502-8640","authenticated-orcid":false,"given":"Katie","family":"Larner","sequence":"additional","affiliation":[{"name":"Triducive Partners Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-895X","authenticated-orcid":false,"given":"Vijay","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Hospital for Sick Children and University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"S0317167125104095_ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10996-y"},{"key":"S0317167125104095_ref28","first-page":"E32829","article-title":"Use of Delphi in health sciences research: a narrative review","volume":"102","author":"Shang","year":"2023","journal-title":"Med(USA)"},{"key":"S0317167125104095_ref30","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2024.2324117"},{"key":"S0317167125104095_ref9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac146"},{"key":"S0317167125104095_ref26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1601827113"},{"key":"S0317167125104095_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phoj.2023.05.002"},{"key":"S0317167125104095_ref33","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000950"},{"key":"S0317167125104095_ref36","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61125"},{"key":"S0317167125104095_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsae006"},{"key":"S0317167125104095_ref23","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2006.045906"},{"key":"S0317167125104095_ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03420-6"},{"key":"S0317167125104095_ref31","first-page":"57","article-title":"Pigmented neurofibroma with hypertrichosis","volume":"80","author":"God\u00ednez-Chaparro","year":"2023","journal-title":"Bol Med Hosp Infant Mex"},{"key":"S0317167125104095_ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012421"},{"key":"S0317167125104095_ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-020-04731-2"},{"key":"S0317167125104095_ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.886697"},{"key":"S0317167125104095_ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.39.5.311"},{"key":"S0317167125104095_ref1","first-page":"i141","article-title":"Quality of life in patients with neurofibromatosis type 1 and 2 in Canada","volume":"2","author":"Hamoy-Jimenez","year":"2020","journal-title":"Neurooncol Adv"},{"key":"S0317167125104095_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01155-9"},{"key":"S0317167125104095_ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02493-5"},{"key":"S0317167125104095_ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01451-z"},{"key":"S0317167125104095_ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38680"},{"key":"S0317167125104095_ref25","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0660"},{"key":"S0317167125104095_ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01170-5"},{"key":"S0317167125104095_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"S0317167125104095_ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05361-5"},{"key":"S0317167125104095_ref27","first-page":"686","article-title":"Evidence for a collective intelligence factor in the performance of human groups","volume":"330","author":"Woolley","year":"2010","journal-title":"Science (1979)"},{"key":"S0317167125104095_ref21","doi-asserted-by":"publisher","DOI":"10.1080\/24694193.2020.1806402"},{"key":"S0317167125104095_ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91345-6"},{"key":"S0317167125104095_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2017.11.003"},{"key":"S0317167125104095_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2023.104734"},{"key":"S0317167125104095_ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605943"},{"key":"S0317167125104095_ref35","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0069"},{"key":"S0317167125104095_ref3","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1940907"},{"key":"S0317167125104095_ref34","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac165"},{"key":"S0317167125104095_ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01034"},{"key":"S0317167125104095_ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02927-2"},{"key":"S0317167125104095_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100223"},{"key":"S0317167125104095_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2017.09.004"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167125104095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:57:33Z","timestamp":1789138653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167125104095\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0317167125104095"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2025.10409","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]}}}